Market Cap 128.66B
Revenue (ttm) 47.92B
Net Income (ttm) 6.02B
EPS (ttm) N/A
PE Ratio 12.24
Forward PE 11.58
Profit Margin 12.55%
Debt to Equity Ratio 0.21
Volume 3,051,970
Avg Vol 2,892,732
Day's Range N/A - N/A
Shares Out 2.53B
Stochastic %K 91%
Beta 0.57
Analysts Strong Sell
Price Target $63.93

Latest News on SNY

US FDA approves Sanofi's bleeding disorder therapy

Mar 28, 2025, 2:27 PM EDT - 26 days ago

US FDA approves Sanofi's bleeding disorder therapy


AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

Mar 28, 2025, 9:44 AM EDT - 26 days ago

AbbVie Vs. Sanofi: Which Is The Better Investment Right Now

ABBV


Press Release: Availability of the Q1 2025 Aide mémoire

Mar 24, 2025, 2:30 AM EDT - 4 weeks ago

Press Release: Availability of the Q1 2025 Aide mémoire


Sanofi to acquire Dren Bio's immunology unit

Mar 20, 2025, 2:29 AM EDT - 4 weeks ago

Sanofi to acquire Dren Bio's immunology unit


Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth

Feb 19, 2025, 7:19 AM EST - 2 months ago

Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth


Sanofi (SNY) Q4 2024 Earnings Call Transcript

Jan 30, 2025, 2:41 PM EST - 2 months ago

Sanofi (SNY) Q4 2024 Earnings Call Transcript


Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance

Jan 30, 2025, 10:30 AM EST - 2 months ago

Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance


Press Release: Opella reaches study milestone for Cialis

Jan 21, 2025, 1:00 AM EST - 3 months ago

Press Release: Opella reaches study milestone for Cialis


Top 4 Immunology Stocks Poised For Growth In 2025

Jan 19, 2025, 4:54 PM EST - 3 months ago

Top 4 Immunology Stocks Poised For Growth In 2025

ABBV BMY TEVA